Aclaris Therapeutics (ACRS) Price & Analysis

Compare

752 Followers

ACRS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $5.17

Previous CloseN/A

Volume227.82K

Average Volume (3M)677.24K

Market Cap

$153.76M

Enterprise Value$982.53M

Total Cash (Recent Filing)$105.31M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.48

Next Earnings

Aug 06, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding108,281,240

10 Day Avg. Volume607,244

30 Day Avg. Volume677,240

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)5.20

Price to Sales (P/S)0.00

P/FCF Ratio-15.07

Enterprise Value/Market Cap6.39

Enterprise Value/Revenue10.28

Enterprise Value/Gross Profit268.89

Enterprise Value/Ebitda-3.95

Forecast

1Y Price Target

$9.40

Price Target Upside561.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Aclaris Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial AdvancementsBosakitug mid-stage atopic dermatitis trial started on schedule.

Financial OutlookACRS has a cash runway into 2028, supporting its operations for several more years.

Pipeline PotentialBosakitug possesses superior potency and residence time along with unique TSLP binding characteristics, which may position it as a potential best-in-class anti-TSLP therapeutic monoclonal antibody.

Bears Say

Market Competition'045 and '052 demonstrated superior potency, shorter dissociation curves, and longer residence times compared to TSLP competitors, which could translate into promising efficacy.

Proof Of Concept SkepticismInvestors view Teze data as proof of concept for TSLP inhibition, lending support for '045 despite Teze's discontinuation in AD.

Trial Design ConcernsThe lack of a placebo control in the open-label Ph2a trial for '045 requires caution, even though investors see the data as promising.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

29.21% Insiders

5.02% Mutual Funds

0.68% Other Institutional Investors

58.27% Public Companies and Individual Investors

Detailed Ownership Overview >

ACRS FAQ

What was Aclaris Therapeutics’s price range in the past 12 months?

Aclaris Therapeutics lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.

What is Aclaris Therapeutics’s market cap?

Aclaris Therapeutics’s market cap is $153.76M.

When is Aclaris Therapeutics’s upcoming earnings report date?

Aclaris Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 46 days.

How were Aclaris Therapeutics’s earnings last quarter?

Aclaris Therapeutics released its earnings results on May 08, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.032.

Is Aclaris Therapeutics overvalued?

According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics does not currently pay dividends.

What is Aclaris Therapeutics’s EPS estimate?

Aclaris Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Aclaris Therapeutics have?

Aclaris Therapeutics has 108,281,240 shares outstanding.

What happened to Aclaris Therapeutics’s price movement after its last earnings report?

Aclaris Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went up 4.8%.

Which hedge fund is a major shareholder of Aclaris Therapeutics?

Currently, no hedge funds are holding shares in ACRS

Aclaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-91.03%

Trailing 12-Months

Asset Growth

13.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a biopharmaceutical company that operates in the healthcare sector, focusing on the development and commercialization of innovative therapies for dermatological and immuno-inflammatory diseases. The company is engaged in the research and development of small molecule therapies that aim to address significant unmet medical needs. Aclaris's core products include drug candidates targeting specific enzymes and pathways relevant to dermatological conditions, such as alopecia areata and vitiligo.

ACRS Stock 12 Month Forecast

Average Price Target

$9.40

▲(561.97%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.56,3.68,4.800000000000001,5.92,7.040000000000001,8.16,9.280000000000001,10.4,11.520000000000001,12.64,13.76,14.88,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.0523076923076924,2.6646153846153844,3.276923076923077,3.8892307692307693,4.501538461538462,5.113846153846154,5.726153846153846,6.338461538461539,6.950769230769231,7.563076923076924,8.175384615384615,8.787692307692307,{"y":9.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.8676923076923075,2.2953846153846156,2.723076923076923,3.1507692307692308,3.5784615384615384,4.006153846153847,4.433846153846154,4.861538461538462,5.28923076923077,5.716923076923077,6.144615384615385,6.572307692307692,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >